XTL-001. XTL Pharmaceuticals.


XTL-001, a combination of two human high-affinity monoclonal antibodies with affinity to different regions of the HBV surface antigen (HBsAg), is under development by XTL Biopharmaceuticals as a potential passive immunotherapy for HBV infection. An IND for XTL-001 was submitted in the third quarter of 1998 and was approved by the FDA in March 1999. It has… (More)


Figures and Tables

Sorry, we couldn't extract any figures or tables for this paper.

Slides referencing similar topics